What are the odds of getting sick from plastic food containers?
Evidence quality 4.5/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 3/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 16,949
0.006% lifetime chance
Most people overestimate this.
range 1 in 1,000,000 to 1 in 1,000
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Plastic food containers occupy a durable position in the hierarchy of kitchen anxieties. The core narrative is simple: chemicals leach from plastic into food, especially when heated, and those chemicals cause cancer, hormonal disruption, or fertility problems. BPA became the emblematic villain after a wave of 2008-era media coverage, and the subsequent "BPA-free" labeling campaign reinforced the idea that standard plastic containers were delivering a meaningful dose of something dangerous. CDC biomonitoring data showing detectable BPA in over 90% of Americans cemented the perception of universal, involuntary exposure. Surveys consistently find that a majority of US adults express concern about chemicals leaching from food packaging, and many report avoiding microwaving food in plastic containers specifically because of cancer or hormone fears.
Rough estimate: Most consumers treat plastic food containers as a moderate ongoing health threat
Source: editorial intuition, not polled
Actual
~1 per 1,000,000 US adults per year attributable illness from food-contact plastic leaching
US adults using standard food-grade plastic containers
Show derivation
No published epidemiological cohort has isolated a statistically significant increase in cancer, endocrine disease, or other illness attributable specifically to BPA or phthalate exposure from food-contact plastics at levels encountered in normal consumer use. CDC NHANES data (2003-2016) show >90% of US adults have detectable urinary BPA, confirming universal exposure, but detection is not disease. FDA's 2014 four-year review of over 300 studies concluded BPA is safe at current exposure levels. EFSA's 2023 re-evaluation lowered the TDI 20,000-fold to 0.2 ng/kg/day and concluded dietary exposure exceeds this new threshold — but the EFSA opinion is based on immune-cell changes in mice (Th17 shifts) extrapolated via benchmark dose modeling, not on observed human illness. The FDA-EFSA disagreement is unresolved. The 1-in-1,000,000 annual rate is a conservative placeholder reflecting that attributable human illness has not been measured; compounded over 59 adult-remaining years gives ~5.9e-5. The true figure could be effectively zero (if FDA is right) or modestly higher (if EFSA's low-dose immune effects translate to clinical disease). The wide uncertainty band reflects this regulatory divergence, not measured variability.
Caveats: This entry addresses illness risk from chemical leaching (BPA, phthalates, bisph…
This entry addresses illness risk from chemical leaching (BPA, phthalates, bisphenol analogues) from food-grade plastic containers during normal consumer use. It does not cover microplastics or nanoplastics, which are addressed in a separate entry (microplastics-health-harm). The FDA-EFSA disagreement on BPA safety is genuine and unresolved: FDA maintains current exposure is safe, EFSA says it is not. The normalized probability reflects this uncertainty with a wide band. The placeholder figure of ~1 in 17,000 lifetime is a modeling estimate, not a measured epidemiological finding — no cohort study has quantified attributable illness from food-contact plastic leaching in the general population.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
PLA bioplastic harm
What are the odds of getting sick from PLA bioplastic or "compostable" food packaging?
Food left out
What are the odds of getting food poisoning from eating food left out of the fridge?
Acrylamide & cancer
How much does dietary acrylamide from fried or baked starchy foods actually raise cancer risk?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The gap between BPA anxiety and BPA evidence is wide, but the story is more complicated than either “perfectly safe” or “slow-motion poisoning.” CDC biomonitoring confirms that over 90% of Americans have detectable urinary BPA, a number that made headlines but says nothing about dose-response. FDA reviewed more than 300 studies over four years and concluded in 2014 that BPA is safe at current dietary exposure levels, a position it has not revised. EFSA, reviewing much of the same literature with different uncertainty factors, reached the opposite conclusion in April 2023: it lowered the tolerable daily intake 20,000-fold to 0.2 nanograms per kilogram of body weight per day, a threshold that essentially every human alive exceeds through diet alone. The EU subsequently banned BPA in food-contact materials in December 2024. The critical effect driving EFSA’s revision is a shift in Th17 immune cells in mouse spleen tissue — a measurable biological change, but not one that has been linked to clinical disease in any human cohort.
The “BPA-free” label, meanwhile, may be a case study in regrettable substitution. BPS and BPF, the most common replacements, show comparable estrogenic and anti-androgenic activity in laboratory assays. A 2024 Environmental Sciences Europe analysis of eleven bisphenol analogues found that most matched or exceeded BPA’s endocrine-disrupting profile in vitro. Washington State University researchers reported chromosomal abnormalities from BPS and BPF resembling those seen with BPA. Consumers who switched to “BPA-free” containers may have traded one poorly characterized exposure for another, while gaining a false sense of safety. The one behavioral change that unambiguously reduces leaching — using glass or stainless steel for food storage and reheating — does not require reading labels at all.
The single most-cited epidemiological finding, Bao et al. 2020 in JAMA Network Open, reported a hazard ratio of 1.49 for all-cause mortality in the highest versus lowest BPA tertile among NHANES participants. It is an observational study using a single spot urine measurement of a chemical with a six-hour half-life as a proxy for chronic exposure, in a population where higher BPA likely correlates with more processed food, less home cooking, and a constellation of lifestyle factors that independently predict mortality. No randomized trial or Mendelian randomization study has confirmed the association. The honest summary: universal exposure is real, regulatory agencies disagree on whether it matters, and no human cohort has measured attributable illness from food-contact plastic at population scale.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] US Environmental Protection Agency — Biomonitoring - Bisphenol A (BPA)
Biomonitoring - Bisphenol A (BPA)- Statistic
92.6% of US residents aged 6+ had detectable urinary BPA in NHANES 2003-2004; median levels declined from 3 µg/L (2003-2004) to 1 µg/L (2015-2016)- Excerpt
“"Total BPA was detected in 92.6% of participants, with concentrations ranging from 0.4 to 149 ng/mL and a geometric mean of 2.6 ng/mL urine." ”
- Source data from
- 2022-06-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- EPA's summary of CDC NHANES biomonitoring data confirms near-universal BPA exposure in the US population. The declining trend (geometric mean from 2.6 ng/mL in 2003-2004 to lower levels in 2015-2016) likely reflects voluntary industry phase-out of BPA from many consumer products. However, detection of a chemical in urine establishes exposure, not harm. The dose-response question — whether these exposure levels cause illness — is the crux of the FDA-EFSA disagreement. Used here to document the exposure side of the risk equation.
- Independence
- EPA summarizes CDC NHANES biomonitoring data; treat as a consolidated federal source on exposure prevalence, not as an independent risk assessment.
-
[2] US Food and Drug Administration — Bisphenol A (BPA): Use in Food Contact Application
Bisphenol A (BPA): Use in Food Contact Application- Statistic
FDA considers BPA safe at the current levels occurring in foods based on ongoing review of scientific evidence- Excerpt
“"Based on FDA's ongoing safety review of scientific evidence, the available information continues to support the safety of BPA for the currently approved uses in food containers and packaging." ”
- Source data from
- 2024-11-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- FDA's position rests on its 2014 review of over 300 studies and subsequent updates, including the CLARITY-BPA study. FDA concluded that dietary BPA exposure for US consumers is far below levels that would cause health effects in toxicological studies. FDA banned BPA from baby bottles and sippy cups in 2012, but this was based on market abandonment rather than a safety finding. FDA has acknowledged EFSA's 2023 re-evaluation but has not revised its own safety assessment or TDI in response. The FDA position anchors the low end of the uncertainty band.
- Independence
- FDA's BPA safety assessment is an independent regulatory review from EFSA's 2023 re-evaluation; the two agencies used overlapping but not identical study sets and reached divergent conclusions.
-
[3] European Food Safety Authority (EFSA) — Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs
Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs- Statistic
EFSA established a new TDI of 0.2 ng BPA/kg bw/day — 20,000x lower than the previous temporary TDI of 4 µg/kg/day — and concluded dietary BPA exposure is a health concern for all age groups- Excerpt
“"Both the mean and the 95th percentile dietary exposures in all age groups exceeded the TDI by two to three orders of magnitude, and the CEP Panel concluded that there is a health concern from dietary BPA exposure." ”
- Source data from
- 2023-04-19
- Accessed
- 2026-04-18 · archived copy
- Calculation
- EFSA's 2023 re-evaluation represents the most dramatic regulatory shift on BPA in decades. The new TDI of 0.2 ng/kg/day is based on a benchmark dose analysis of Th17 cell increases in mouse spleen, interpreted as an immunotoxic effect. At this threshold, essentially all dietary BPA exposure in all age groups exceeds the TDI by 100-1,000x. However, the critical effect is a cell-count shift in mice, not observed disease in humans. No epidemiological study has demonstrated the immune effects EFSA extrapolated from animal data. FDA, Health Canada, and Food Standards Australia New Zealand have not adopted EFSA's revised TDI. The EU adopted a ban on BPA in food contact materials in December 2024 based on this opinion.
- Independence
- EFSA's re-evaluation is methodologically independent of FDA's assessment; the two agencies reviewed overlapping literature but applied different uncertainty factors and critical-effect selections, producing divergent safety conclusions.
-
[4] Biochemical Pharmacology / Molina-Molina et al. — BPS and BPF are as Carcinogenic as BPA and are Not Viable Alternatives for its Replacement
BPS and BPF are as Carcinogenic as BPA and are Not Viable Alternatives for its Replacement- Statistic
BPS and BPF exhibit estrogenic and anti-androgenic activities comparable to BPA in in vitro assays, suggesting BPA-free substitutions may not reduce endocrine-disrupting exposure- Excerpt
“"BPS and BPF are as carcinogenic as BPA and are not viable alternatives for its replacement." ”
- Source data from
- 2022-03-15
- Accessed
- 2026-04-18 · archived copy
- Calculation
- This study is relevant because "BPA-free" labeling has driven a massive consumer shift toward products using bisphenol S (BPS) and bisphenol F (BPF) as replacements. Multiple studies, including a 2024 Environmental Sciences Europe analysis of 11 BPA analogues, find comparable or greater endocrine-disrupting potency in vitro. Washington State University research found BPS and BPF produce chromosomal abnormalities similar to BPA. If BPA substitutes carry similar biological activity, then "BPA-free" labeling may represent regrettable substitution rather than risk reduction. This does not change the population-level illness estimate — none of these analogues have demonstrated attributable human disease either — but it undermines the consumer assumption that switching to BPA-free containers meaningfully reduces exposure.
- Independence
- Independent laboratory study of bisphenol analogues; not funded by or methodologically dependent on FDA or EFSA assessments.
-
[5] JAMA Network Open / Bao et al. — Association Between Bisphenol A Exposure and Risk of All-Cause and Cause-Specific Mortality in US Adults
Association Between Bisphenol A Exposure and Risk of All-Cause and Cause-Specific Mortality in US Adults- Statistic
Highest vs lowest BPA tertile associated with HR 1.49 (95% CI 1.22-1.82) for all-cause mortality in NHANES 2003-2008 cohort followed through 2015- Excerpt
“"Higher urinary BPA was associated with increased risk of all-cause mortality after adjusting for demographic, lifestyle, dietary, and clinical factors." ”
- Source data from
- 2020-08-14
- Accessed
- 2026-04-18 · archived copy
- Calculation
- Bao et al. analyzed 3,883 NHANES participants aged 20+ with urinary BPA measurements and mortality follow-up through the National Death Index. The adjusted HR of 1.49 for all-cause mortality in the highest BPA tertile is one of the more alarming findings in the BPA literature, but it is a single observational study with a single spot urine measurement as the exposure metric. BPA has a half-life of ~6 hours, so a single measurement is a poor proxy for chronic exposure. Residual confounding is likely: higher BPA exposure may correlate with more processed-food consumption, less cooking at home, and other lifestyle factors that independently affect mortality. No randomized or Mendelian randomization study has confirmed a causal link. This study is included because it represents the strongest epidemiological signal in the BPA literature, but its design limitations prevent it from establishing an attributable mortality fraction suitable for the normalized probability calculation.
- Independence
- Independent NHANES cohort analysis; methodologically distinct from FDA and EFSA regulatory reviews, though it uses the same underlying NHANES biomonitoring data cited by EPA.